Literature DB >> 13354120

Clot formation in the common duct; an unusual manifestation of primary hepatic carcinoma.

D L CREED, E R FISHER.   

Abstract

Entities:  

Keywords:  BILE DUCT, COMMON/diseases; LIVER/neoplasms

Mesh：

Year:  1956        PMID： 13354120     DOI： 10.1001/archsurg.1956.01280020075014

Source DB:  PubMed          Journal:  AMA Arch Surg        ISSN： 0096-6908


× No keyword cloud information.
  8 in total

1.  Biliary obstruction due to hemobilia caused by liver cell carcinoma.

Authors:  W A JOHNS; A ZIMMERMAN
Journal:  Ann Surg       Date:  1961-05       Impact factor: 12.969

2.  Extrahepatic biliary tract obstruction secondary to a hepatoma-containing blood clot in the common bile duct.

Authors:  S N Brand; L J Brandt; S Sprayregan; S Brenner; L H Bernstein
Journal:  Am J Dig Dis       Date:  1976-10

3.  Hepatoma presenting as extrahepatic biliary obstruction. Report of a case.

Authors:  C D Gerson; R A Schinella
Journal:  Am J Dig Dis       Date:  1969-01

4.  Formation and fate of fibrin clots in the biliary tract: a clinical and experimental study.

Authors:  P Sandblom; V Mirkovitch; F Saegesser
Journal:  Ann Surg       Date:  1977-03       Impact factor: 12.969

5.  Hemobilia following percutaneous transhepatic cholangiography.

Authors:  C E Cahow; M Burrell; R Greco
Journal:  Ann Surg       Date:  1977-02       Impact factor: 12.969

6.  A prospective study of upper gastrointestinal hemorrhage in patients with hepatocellular carcinoma.

Authors:  W Yeo; J Y Sung; S C Ward; S C Chung; W Y Lee; A K Li; P J Johnson
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

7.  Minor hemobilia. Clinical significance and pathophysiological background.

Authors:  P Sandblom; V Mirkovitch
Journal:  Ann Surg       Date:  1979-08       Impact factor: 12.969

8.  Surgical treatment for hepatocellular carcinoma with bile duct invasion.

Authors:  Xu-Guang Hu; Wei Mao; Sung Yeon Hong; Bong-Wan Kim; Wei-Guang Xu; Hee-Jung Wang
Journal:  Ann Surg Treat Res       Date:  2016-02-26       Impact factor: 1.859
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.